Ascletis Pharma, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jinzi J. Wu
- Full Time Employees
- 202
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Dah Sing Financial Centre Hangzhou ZH China 311200
- IPO Date
- Aug 1, 2018
- Website
- ascletis.com
- Similar Companies
- Business
- Ascletis Pharma Inc., a biotechnology firm, focuses on the discovery, development, production, and commercialization of pharmaceutical innovations across Mainland China and global markets. The company currently offers several commercialized products, including its Ritonavir oral tablet, which functions as a pharmacokinetic enhancer for various oral antiviral medications and is a component of the antiviral treatment Paxlovid, alongside ASCLEVIR and GANOVO for managing Hepatitis C virus infections. The company is strategically shifting its research and development efforts, with a pronounced focus on metabolic diseases, particularly obesity. Its pipeline now features ASC30, an oral and subcutaneous GLP-1 receptor agonist in advanced clinical trials for weight management, with Phase IIa enrollment completed and topline data anticipated in late 2025. Further candidates in this area include ASC36, a once-monthly subcutaneously administered amylin receptor agonist, and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual agonist, both aimed at chronic weight management, alongside ASC47, an adipose-targeted, muscle-preserving therapy. Ascletis also progresses ASC41, a THRβ agonist for metabolic dysfunction-associated steatohepatitis (MASH), which has demonstrated positive interim Phase II results, and ASC40, a FASN inhibitor, now in Phase III for moderate to severe acne with positive endpoint achievements, and also advancing in Phase II for MASH. While recalibrating its portfolio, the company continues to develop ASC10 and ASC11 as oral small molecule therapies for COVID-19, with ASC10 also receiving U.S. FDA IND approval for monkeypox, and maintains select oncology programs, such as ASC40 for recurrent glioblastoma and ASC61 for advanced solid tumors. Founded in 2011, Ascletis Pharma Inc. maintains its headquarters in Hangzhou, People's Republic of China.
Company News
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor